Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gen 2 Travoprost Intracameral Implant in Open-Angle Glaucoma or Ocular Hypertension
NCT07495852Phase 3Recruiting
- Sponsor
- Glaukos Corporation
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (6 cohorts), sponsored by Glaukos Corporation. Primary endpoint: Intraocular pressure at 3 months. Started Feb 2026; status: recruiting.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT07495852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495852.